Literature DB >> 27106297

The Role of Psychotropic Medications in the Management of Anorexia Nervosa: Rationale, Evidence and Future Prospects.

Guido K W Frank1,2, Megan E Shott3.   

Abstract

Anorexia nervosa (AN) is a severe psychiatric disorder without approved medication intervention. Every class of psychoactive medication has been tried to improve treatment outcome; however, randomized controlled trials have been ambiguous at best and across studies have not shown robust improvements in weight gain and recovery. Here we review the available literature on pharmacological interventions since AN came to greater public recognition in the 1960s, including a critical review of why those trials may not have been successful. We further provide a neurobiological background for the disorder and discuss how cognition, learning, and emotion-regulating circuits could become treatment targets in the future. Making every effort to develop effective pharmacological treatment options for AN is imperative as it continues to be a complex psychiatric disorder with high disease burden and mortality.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27106297      PMCID: PMC4873415          DOI: 10.1007/s40263-016-0335-6

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  188 in total

1.  Olanzapine use for the adjunctive treatment of adolescents with anorexia nervosa.

Authors:  Mark L Norris; Wendy Spettigue; Annick Buchholz; Katherine A Henderson; Rebecca Gomez; Danijela Maras; Isabelle Gaboury; Andy Ni
Journal:  J Child Adolesc Psychopharmacol       Date:  2011-04-21       Impact factor: 2.576

2.  Rapid improvement of severe anorexia nervosa during treatment with ethyl-eicosapentaenoate and micronutrients.

Authors:  Agnes K Ayton; Amer Azaz; David F Horrobin
Journal:  Eur Psychiatry       Date:  2004-08       Impact factor: 5.361

3.  Fluoxetine-induced anorexia in a bulimic patient.

Authors:  S C Oliveros; L M Iruela; L Caballero; E Baca
Journal:  Am J Psychiatry       Date:  1992-08       Impact factor: 18.112

4.  The impact of comorbid depressive and anxiety disorders on severity of anorexia nervosa in adolescent girls.

Authors:  Ayelet Brand-Gothelf; Shani Leor; Alan Apter; Silvana Fennig
Journal:  J Nerv Ment Dis       Date:  2014-10       Impact factor: 2.254

5.  Brain type 1 cannabinoid receptor availability in patients with anorexia and bulimia nervosa.

Authors:  Nathalie Gérard; Guido Pieters; Karolien Goffin; Guy Bormans; Koen Van Laere
Journal:  Biol Psychiatry       Date:  2011-06-29       Impact factor: 13.382

6.  'Why I won't eat': patient testimony from 15 anorexics concerning the causes of their disorder.

Authors:  Andrée Dignon; Angela Beardsmore; Sean Spain; Ann Kuan
Journal:  J Health Psychol       Date:  2006-11

7.  Fenfluramine treatment in female rats accelerates the weight loss associated with activity-based anorexia.

Authors:  Deann P D Atchley; Lisa A Eckel
Journal:  Pharmacol Biochem Behav       Date:  2004-12-19       Impact factor: 3.533

8.  Amitriptyline in the treatment of anorexia nervosa: a double-blind, placebo-controlled study.

Authors:  J Biederman; D B Herzog; T M Rivinus; G P Harper; R A Ferber; J F Rosenbaum; J S Harmatz; R Tondorf; P J Orsulak; J J Schildkraut
Journal:  J Clin Psychopharmacol       Date:  1985-02       Impact factor: 3.153

9.  Monoamine oxidase inhibitor therapy for anorexia nervosa and bulimia: a preliminary trial of isocarboxazid.

Authors:  S H Kennedy; N Piran; P E Garfinkel
Journal:  J Clin Psychopharmacol       Date:  1985-10       Impact factor: 3.153

10.  A double-blind controlled trial of lithium carbonate primary anorexia nervosa.

Authors:  H A Gross; M H Ebert; V B Faden; S C Goldberg; L E Nee; W H Kaye
Journal:  J Clin Psychopharmacol       Date:  1981-11       Impact factor: 3.153

View more
  19 in total

1.  Psychotropic usage by patients presenting to an academic eating disorders program.

Authors:  Karuna Mizusaki; Daniel Gih; Christina LaRosa; Rebekah Richmond; Renee D Rienecke
Journal:  Eat Weight Disord       Date:  2018-06-07       Impact factor: 4.652

2.  The partial dopamine D2 receptor agonist aripiprazole is associated with weight gain in adolescent anorexia nervosa.

Authors:  Guido K W Frank; Megan E Shott; Jennifer O Hagman; Marissa A Schiel; Marisa C DeGuzman; Brogan Rossi
Journal:  Int J Eat Disord       Date:  2017-03-23       Impact factor: 4.861

3.  Olanzapine Versus Placebo in Adult Outpatients With Anorexia Nervosa: A Randomized Clinical Trial.

Authors:  Evelyn Attia; Joanna E Steinglass; B Timothy Walsh; Yuanjia Wang; Peng Wu; Colleen Schreyer; Jennifer Wildes; Zeynep Yilmaz; Angela S Guarda; Allan S Kaplan; Marsha D Marcus
Journal:  Am J Psychiatry       Date:  2019-01-18       Impact factor: 18.112

Review 4.  Motivation to eat and not to eat - The psycho-biological conflict in anorexia nervosa.

Authors:  Guido K W Frank; Marisa C DeGuzman; Megan E Shott
Journal:  Physiol Behav       Date:  2019-04-10

Review 5.  Structural Neuroimaging of Anorexia Nervosa: Future Directions in the Quest for Mechanisms Underlying Dynamic Alterations.

Authors:  Joseph A King; Guido K W Frank; Paul M Thompson; Stefan Ehrlich
Journal:  Biol Psychiatry       Date:  2017-08-24       Impact factor: 13.382

6.  Food Restriction Engages Prefrontal Corticostriatal Cells and Local Microcircuitry to Drive the Decision to Run versus Conserve Energy.

Authors:  Adrienne N Santiago; Emily A Makowicz; Muzi Du; Chiye Aoki
Journal:  Cereb Cortex       Date:  2021-05-10       Impact factor: 5.357

Review 7.  Psychosocial etiology of maladaptive exercise and its role in eating disorders: A systematic review.

Authors:  Sasha Gorrell; Rachael E Flatt; Cynthia M Bulik; Daniel Le Grange
Journal:  Int J Eat Disord       Date:  2021-05-04       Impact factor: 5.791

8.  Vulnerable and Resilient Phenotypes in a Mouse Model of Anorexia Nervosa.

Authors:  Jeff A Beeler; Devry Mourra; Roseanna M Zanca; Abigail Kalmbach; Celia Gellman; Benjamin Y Klein; Rebecca Ravenelle; Peter Serrano; Holly Moore; Stephen Rayport; Susana Mingote; Nesha S Burghardt
Journal:  Biol Psychiatry       Date:  2020-07-16       Impact factor: 13.382

Review 9.  Pharmacotherapeutic strategies for the treatment of anorexia nervosa - too much for one drug?

Authors:  Guido K W Frank
Journal:  Expert Opin Pharmacother       Date:  2020-04-13       Impact factor: 3.889

10.  Risk factors for eating disorders: an umbrella review of published meta-analyses.

Authors:  Marco Solmi; Joaquim Radua; Brendon Stubbs; Valdo Ricca; Davide Moretti; Daniele Busatta; Andre F Carvalho; Elena Dragioti; Angela Favaro; Alessio Maria Monteleone; Jae Il Shin; Paolo Fusar-Poli; Giovanni Castellini
Journal:  Braz J Psychiatry       Date:  2020-09-28       Impact factor: 2.697

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.